SPOTLIGHT: Akela faces delay

Akela Pharma says it's facing a delay developing Fentanyl Taifun for breakthrough cancer pain after the FDA rejected toxicology studies saying that deviations in Good Laboratory Practice had invalidated the results. Akela says that the decision won't delay its submission for regulatory approval by more than six months. Fentanyl Taifun is a formulation of Fentanyl delivered by Akela's Taifun inhaler technology. Release